Pharmaceutical company developing drugs for hyperoxaluria, particularly in children
Employees: 11-50
Total raised: $54.14M
Founded date: 2005
Investors 6
| Date | Name | Website |
| - | Idinvest P... | idinvest.c... |
| - | Flerie Inv... | flerie.com |
| - | Ysios Capi... | ysioscapit... |
| - | Industrifo... | industrifo... |
| - | Kurma Part... | kurmapartn... |
| - | Life Scien... | lspvc.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 29.11.2016 | - | $34.08M | - |
| 16.04.2014 | - | $10.61M | - |
| - | - | $9.45M | - |
Mentions in press and media 9
| Date | Title | Description |
| 30.11.2016 | Term Sheet — Wednesday, November 30 | ET CETERA • Startups in India: Accel has raised $450 million for its fifth India fund, a sizable jump over its $305 million fourth fund that was announced just last year. The raise comes at an uncertain time for Indian startups, which don’t... |
| 30.11.2016 | Ysios Capital colidera una ronda de €32 millones en la sueca OxThera | 30/11/2016 YSIOS CAPITAL COLIDERA UNA RONDA DE €32 MILLONES EN LA SUECA OXTHERA. La entidad de capital riesgo (venture capital) Ysios Capital, ha anunciado hoy su participación en la ronda de financiación de la compañía OxThera por un imp... |
| 29.11.2016 | OxThera Raises €32M in Funding | OxThera, a Stockholm, Sweden-based biopharmaceutical company, raised €32m in funding. The round was co-led by Life Sciences Partners, Ysios Capital, Sunstone Capital, and Flerie Invest, with participation from current shareholders Kurma Par... |
| 29.11.2016 | OxThera Raises EUR 32 Million to Complete Development of Oxabact® for Treatment of Primary Hyperoxaluria | - |
| 17.11.2014 | Allena Pharma’s kidney stone-preventing enzyme attracts $25M | The company was founded in 2011, with a $15 million Series A cash infusion led by Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. This current round has seven investors. The key indication here is hyperoxaluria – a po... |
| 16.04.2014 | OxThera Raises SEK70M in Funding | OxThera AB, a Stockholm, Sweden-based biopharmaceutical company, raised SEK70m in new funding. The round was led by Kurma Partners, with participation from IdInvest Partners and Mayo Clinic, and current shareholders. In conjunction with the... |
| - | OxThera closes new financing of EUR 8 million | New investors Kurma Biofund, IdInvest Partners and Mayo Clinic together with OxThera´s existing investors provide for the on-going clinical development program. Read More |
| - | Allena Pharma’s kidney stone-preventing enzyme attracts $25M | Kidney stones are on the rise. One cause is a condition called hyperoxaluria – a potentially serious metabolic disorder that’s found in about 20-30 percent of patients with recurrent stones. It that lead to chronic kidney disease, end-stage... |
| - | OxThera initiates clinical trial in Primary Hyperoxaluria | OxThera initiates clinical trial in Primary Hyperoxaluria January 08, 2014 OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in in Primary Hyperoxaluria. This ann... |